Neurovirulence, viscerotropism and immunogenicity of live attenuated yellow fever 17D vaccine virus in non-human primates

Vaccine. 2023 Jan 16;41(3):836-843. doi: 10.1016/j.vaccine.2022.12.029. Epub 2022 Dec 21.

Abstract

Yellow fever vaccine associated neurovirulence and viscerotropism have been reported by various countries. In this study, the neurovirulence, viscerotropism and immunogenicity of yellow fever vaccine seed lots (master and working) and final product manufactured at Serum Institute of India (SII) were evaluated in cynomolgus monkeys. WHO reference virus 168-73 and Stamaril™ as a control vaccine was used for comparison. Neurovirulence and viscerotropism scores of the seed lots and final product were lower than Stamaril™. The SII seed virus and vaccine complies to the WHO requirement for neurovirulence, viscerotropism and immunogenicity, when tested in comparison to WHO reference seed virus 168/73. All challenged animals showed 100 % seroconversion as early as day 14 and neutralizing antibody titers were sustainable at day 30 in all animals.

Keywords: Immunogenicity; Neurovirulence; RK 168/73; Stamaril™; Viscerotropism; Yellow fever seed virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Viral
  • Primates
  • Vaccines, Attenuated
  • Yellow Fever Vaccine*
  • Yellow Fever* / prevention & control
  • Yellow fever virus

Substances

  • Yellow Fever Vaccine
  • Antigens, Viral
  • Vaccines, Attenuated